Differences of designer receptor exclusively activated by designer drugs (DREADD) signaling preferences compared to wild type receptors
Mitja Amon Posch, Sarah Seidel, Leandra Abt, Ana Lechuga, Olga Trovato, Germana Thaler, Marita Baur, Moritz Henninger, Andreas Lieb · FENS Forum 2024
DREADDs have revolutionized neuroscience research and hold promise for therapeutic applications. While their ability to modulate neuronal activity is well established, the specific signaling pathways they can trigger remain only partially explored. In this project, we therefore examine the signaling preferences of the human muscarinic acetylcholine receptor M3 and M4 (hM3/4) and the respective DREADDs (hM3D and hM4D). Additionally, we evaluate the impact of the individual single point mutations Y3.33C and A5.46G, which convert the wild type receptors to the DREADD. We investigated signaling of
ePoster · Neuroscience